Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
30 sept. 2021 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Cognitive Impairment in Psychosis: What it is and How it's Treated - A Free Webinar from the Brain & Behavior Research Foundation
08 juil. 2021 09h00 HE
|
Brain & Behavior Research Foundation
New York, July 08, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Cognitive Impairment in Psychosis: What it is and How it's Treated” on...
OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder
01 juil. 2021 08h00 HE
|
OWP Pharmaceuticals, Inc.
NAPERVILLE, Ill., July 01, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Outlook on the Precision Psychiatry Global Market to 2026 - Increasing Adoption of Inorganic Growth Strategies is Driving Growth
09 avr. 2021 07h58 HE
|
Research and Markets
Dublin, April 09, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Psychiatry Market: Focus on Product Type, Biomarker, Sample, Technology, Applications, End Users, Country Data (15 Countries), and...
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
01 déc. 2020 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
07 oct. 2020 08h00 HE
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Oct. 07, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Recent Studies Indicate Brain Training May Provide New Path to Treat Mental Illness
14 juil. 2020 08h00 HE
|
Posit Science
SAN FRANCISCO, July 14, 2020 (GLOBE NEWSWIRE) -- Three recently published studies add significant new evidence that brain training exercises may provide a new path for treating schizophrenia – one...
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
29 mai 2020 09h20 HE
|
Minerva Neurosciences, Inc
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259,...
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
04 mai 2020 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
24 mars 2020 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high...